Health-related quality of life in patients with chronic myeloid leukemia treated with first-versus second-generation tyrosine kinase inhibitors

Adi Shacham Abulafia, Sivan Shemesh, Lena Rosenmann, Tamar Berger, Avi Leader, Giora Sharf, Pia Raanani, Uri Rozovski

Research output: Contribution to journalArticlepeer-review

Abstract

The life expectancy of patients with chronic myeloid leukemia (CML) approaches that of the age-matched population and quality of life (QOL) issues are becoming increasingly important. To describe patients’ characteristics and assess QOL, we delivered a 30-item core questionnaire, a 24-item CML-specific questionnaire, both from the European Organization for Research and Treatment of Cancer (EORTC), and additional health-related items to 350 patients. Among 193 patients who completed the questionnaires, 139 received either imatinib (n = 70, 33%), dasatinib (n = 45, 23%) or nilotinib (n = 24, 12%). Patients’ median age was 58 (range: 23 to 89) years and 86 (63%) were males. Stratifying patients by treatment, we recognized two distinct populations. In comparison to patients on dasatinib and nilotinib, patients on imatinib were two decades older, had a longer duration of disease and current treatment, experienced fewer limitations on daily activities (p = 0.02), less fatigue (p = 0.001), lower degree of impaired body image (p = 0.022) and less painful episodes (p = 0.014). Similarly, they had better emotional functioning, were less worried, stressed, depressed or nervous (p = 0.01) and were more satisfied with their treatment (p = 0.018). Not only does age associate with current treatments, but it also predicts how patients perceive QOL. Young patients express impaired QOL compared with elderly patients.

Original languageEnglish
Article number3417
Pages (from-to)1-9
Number of pages9
JournalJournal of Clinical Medicine
Volume9
Issue number11
DOIs
StatePublished - Nov 2020

Keywords

  • Chronic myeloid leukemia
  • Patient-reported outcome
  • Quality of life
  • Tyrosine kinase inhibitors

Fingerprint

Dive into the research topics of 'Health-related quality of life in patients with chronic myeloid leukemia treated with first-versus second-generation tyrosine kinase inhibitors'. Together they form a unique fingerprint.

Cite this